View Clinical Trial (Medical Research Study)


Safety of Sports for Patients With Implantable Cardioverter-Defibrillators - NCT00637754-Montreal - 001(Clinical Trial 209549)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Montreal
Country:  
Canada
Conditions: Patients With ICD's Who Are Participating in Sports.
Purpose: The registry will obtain information to determine the safety of sports participation for patients with defibrillators (ICDs).
Study summary: Patients who are participating in sports who have defibrillators will be invited to participate in a prospective registry to determine the rate of adverse events occurring during sporting activities. Patients will be followed for two years and adverse events quantified. Yale is the coordinating center for this multicenter registry.
Criteria: Inclusion Criteria: - individuals between the ages of 10 and 60 years - has a defibrillator - plays a competitive/organized sport more vigorous than golf or bowling or participates in a dangerous sport Exclusion Criteria: - children under 10 years (as they engage in primarily recreational sports) - Adults over the age of 60 (to maintain a more homogeneous population) - inability to give informed consent
Study is available at: Institut de Cardiologie de Montreal
Montreal
Canada

Primary Contact:
Cheryl L Barth, BS
Email: icdsports.registry@yale.edu
Phone: 866-207-9813
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.